This lecture summarizes current evidence on the molecular and genetic mechanisms of resistance to HER2targeted breast cancer (BC) therapies. Despite marked improvements in HER2-positive BC treatment, the efficacy of targeted therapy remains suboptimal. Within the first two years after completing combined therapy, 10-15...
O. Bragina, E. Y. Sitnikova, A. A. Nesynov et al.· Bulletin of Siberian Medicin...· 0 citations
This review synthesizes current data on cellular, molecular, and systemic predictors, focusing on immune cell phenotypes, protein biomarkers, gene signatures, and metabolic factors, focusing on immune cell phenotypes, protein biomarkers, gene signatures, and metabolic factors.
E. Tsarenkova, A. Kalinchuk, E. Shmakova et al.· Clinical and Translational O...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.